Human Immunodeficiency Virus Rebound in Blood and Seminal Plasma Following Discontinuation of Antiretroviral Therapy

被引:0
|
作者
Costiniuk, Cecilia T. [1 ]
Kovacs, Colin [2 ,3 ]
Routy, Jean-Pierre [4 ,5 ]
Singer, Joel [6 ]
Gurunathan, Sanjay [7 ]
Sekaly, Rafick-Pierre [8 ]
Angel, Jonathan B. [1 ,9 ]
机构
[1] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Maple Leaf Med Clin, Toronto, ON, Canada
[4] McGill Univ, Div Hematol, Ctr Hlth, Montreal, PQ, Canada
[5] McGill Univ, Serv Immunol, Ctr Hlth, Montreal, PQ, Canada
[6] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada
[7] Sanofi Pasteur, Swiftwater, PA USA
[8] CHU Montreal, Ctr Rech, Montreal, PQ, Canada
[9] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada
基金
加拿大健康研究院;
关键词
SEXUAL TRANSMISSION; HIV-1; TRANSMISSION; SEMEN; INFECTION; INHIBITOR;
D O I
10.1089/aid.2011.0343
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although there is discordance between human immunodeficiency virus (HIV) blood plasma and seminal plasma viral loads (VL), little is known about the dynamics of VL rebound in these compartments upon discontinuation of highly active antiretroviral therapy (HAART). Therefore, we sought to examine the relationship between blood and semen VL rebound after discontinuation of HAART. Participants in this substudy were men enrolled from two centers of a multicenter, placebo-controlled randomized trial of HIV therapeutic vaccination using ALVAC with or without Remune. With at least 2 years of sustained virologic suppression and following a 20-week vaccination course, subjects underwent structured HAART interruption. Fourteen men provided semen samples. Seven to 12 weeks after HAART interruption, all 14 men had detectable blood VLs whereas 8 of 14 had detectable seminal VLs. There was a significant correlation between blood and seminal VLs (Spearman r=0.58, p=0.03) at the time of semen collection. An earlier time to detectable blood VL after HAART interruption was associated with higher seminal VL (Spearman r=-0.64, p=0.02). These findings support the compartmentalization of HIV and underscore the importance of understanding the genital tract as an HIV reservoir in the quest to minimize HIV transmission.
引用
收藏
页码:266 / 269
页数:4
相关论文
共 50 条
  • [1] Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy
    Pasquier, Christophe
    Saune, Karine
    Raymond, Stephanie
    Moinard, Nathalie
    Daudin, Myriam
    Bujan, Louis
    Izopet, Jacques
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (09) : 2883 - 2887
  • [2] Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
    Imamichi, H
    Crandall, KA
    Natarajan, V
    Jiang, MK
    Dewar, RL
    Berg, S
    Gaddam, A
    Bosche, M
    Metcalf, JA
    Davey, RT
    Lane, HC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (01): : 36 - 50
  • [3] Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation
    Bengtson, Angela M.
    Pence, Brian W.
    Mimiaga, Matthew J.
    Gaynes, Bradley N.
    Moore, Richard
    Christopoulos, Katerina
    O'Cleirigh, Conall
    Grelotti, David
    Napravnik, Sonia
    Crane, Heidi
    Mugavero, Michael
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 (03) : 475 - 481
  • [4] Immune reconstitution syndromes in human immunodeficiency virus infection following effective antiretroviral therapy
    Behrens, GMN
    Meyer, D
    Stoll, M
    Schmidt, RE
    [J]. IMMUNOBIOLOGY, 2000, 202 (02) : 186 - 193
  • [5] Antiretroviral therapy in human immunodeficiency virus infection: An update
    Chaix, F.
    Goujard, C.
    [J]. REVUE DE MEDECINE INTERNE, 2009, 30 (06): : 543 - 554
  • [6] Integration of human immunodeficiency virus as a target for antiretroviral therapy
    Semenova, Elena A.
    Johnson, Allison A.
    Marchand, Christophe
    Pommier, Yves
    [J]. CURRENT OPINION IN HIV AND AIDS, 2006, 1 (05) : 380 - 387
  • [7] Antiretroviral therapy for human immunodeficiency virus infection in 1997
    Katzenstein, DA
    [J]. WESTERN JOURNAL OF MEDICINE, 1997, 166 (05): : 319 - 325
  • [8] Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy
    Huang, W
    De Gruttola, V
    Fischl, M
    Hammer, S
    Richman, D
    Havlir, D
    Gulick, R
    Squires, K
    Mellors, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (10): : 1455 - 1465
  • [9] Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection
    Kalapila, Aley G.
    Marrazzo, Jeanne
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2016, 100 (04) : 927 - 950
  • [10] HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption
    Gianella, Sara
    Chaillon, Antoine
    Chun, Tae-Wook
    Sneller, Michael C.
    Ignacio, Caroline
    Vargas-Meneses, Milenka V.
    Caballero, Gemma
    Ellis, Ronald J.
    Kovacs, Colin
    Benko, Erika
    Huibner, Sanja
    Kaul, Rupert
    [J]. JOURNAL OF VIROLOGY, 2020, 94 (15)